-DOCSTART- -X- O
This -X- _ O
longitudinal -X- _ O
study -X- _ O
investigates -X- _ O
the -X- _ O
change -X- _ B-Intervention
of -X- _ I-Intervention
erythrocyte -X- _ I-Intervention
complement -X- _ I-Intervention
receptor -X- _ I-Intervention
( -X- _ I-Intervention
E-CR1 -X- _ I-Intervention
) -X- _ I-Intervention
expression -X- _ I-Intervention
in -X- _ O
patients -X- _ B-Patient
with -X- _ I-Patient
severe -X- _ I-Patient
acute -X- _ I-Patient
respiratory -X- _ I-Patient
syndrome -X- _ I-Patient
( -X- _ I-Patient
SARS -X- _ I-Patient
) -X- _ I-Patient
. -X- _ O
Circulating -X- _ O
E-CR1 -X- _ B-Intervention
expression -X- _ I-Intervention
was -X- _ O
semiquantified -X- _ O
by -X- _ O
flow -X- _ O
cytometric -X- _ O
analyses -X- _ O
in -X- _ O
54 -X- _ O
SARS -X- _ B-Patient
patients -X- _ I-Patient
and -X- _ O
in -X- _ O
212 -X- _ O
healthy -X- _ B-Comparison
individuals -X- _ I-Comparison
as -X- _ I-Comparison
a -X- _ I-Comparison
control. -X- _ I-Comparison
Since -X- _ O
E-CR1 -X- _ B-Intervention
expression -X- _ I-Intervention
is -X- _ O
influenced -X- _ O
by -X- _ O
the -X- _ O
genetic -X- _ O
polymorphisms -X- _ O
in -X- _ O
the -X- _ O
CR1 -X- _ O
gene -X- _ O
, -X- _ O
a -X- _ O
major -X- _ O
genetic -X- _ O
polymorphism -X- _ O
located -X- _ O
within -X- _ O
intron -X- _ O
27 -X- _ O
of -X- _ O
the -X- _ O
CR1 -X- _ O
gene -X- _ O
was -X- _ O
simultaneously -X- _ O
analysed -X- _ O
by -X- _ O
polymerase -X- _ O
chain -X- _ O
reaction -X- _ O
( -X- _ O
PCR -X- _ O
) -X- _ O
and -X- _ O
restriction -X- _ O
fragment -X- _ O
length -X- _ O
polymorphism -X- _ O
( -X- _ O
RFLP -X- _ O
) -X- _ O
. -X- _ O
The -X- _ O
results -X- _ O
showed -X- _ O
that -X- _ O
the -X- _ O
expression -X- _ B-Outcome
level -X- _ I-Outcome
of -X- _ I-Outcome
E-CR1 -X- _ I-Outcome
( -X- _ I-Outcome
referred -X- _ I-Outcome
to -X- _ I-Outcome
as -X- _ I-Outcome
net -X- _ I-Outcome
fluorescence -X- _ I-Outcome
intensity -X- _ I-Outcome
values -X- _ I-Outcome
, -X- _ I-Outcome
NFI -X- _ I-Outcome
) -X- _ I-Outcome
was -X- _ I-Outcome
statistically -X- _ I-Outcome
correlated -X- _ I-Outcome
with -X- _ I-Outcome
the -X- _ I-Outcome
relevant -X- _ I-Outcome
genetic -X- _ I-Outcome
genotypes -X- _ I-Outcome
among -X- _ I-Outcome
the -X- _ I-Outcome
Chinese -X- _ I-Outcome
population -X- _ I-Outcome
including -X- _ I-Outcome
the -X- _ I-Outcome
healthy -X- _ I-Outcome
individuals -X- _ I-Outcome
( -X- _ I-Outcome
NFI -X- _ I-Outcome
: -X- _ I-Outcome
5·14 -X- _ I-Outcome
± -X- _ I-Outcome
0·82 -X- _ I-Outcome
, -X- _ I-Outcome
3·57 -X- _ I-Outcome
± -X- _ I-Outcome
0·66 -X- _ I-Outcome
and -X- _ I-Outcome
2·67 -X- _ I-Outcome
± -X- _ I-Outcome
0·32 -X- _ I-Outcome
for -X- _ I-Outcome
HH -X- _ I-Outcome
, -X- _ I-Outcome
HL -X- _ I-Outcome
and -X- _ I-Outcome
LL -X- _ I-Outcome
genotypes -X- _ I-Outcome
, -X- _ I-Outcome
respectively -X- _ I-Outcome
) -X- _ I-Outcome
and -X- _ I-Outcome
SARS -X- _ I-Outcome
patients -X- _ I-Outcome
( -X- _ I-Outcome
NFI -X- _ I-Outcome
: -X- _ I-Outcome
3·52 -X- _ I-Outcome
± -X- _ I-Outcome
0·91 -X- _ I-Outcome
and -X- _ I-Outcome
2·63 -X- _ I-Outcome
± -X- _ I-Outcome
0·70 -X- _ I-Outcome
for -X- _ I-Outcome
HH -X- _ I-Outcome
and -X- _ I-Outcome
HL -X- _ I-Outcome
genotypes -X- _ I-Outcome
, -X- _ I-Outcome
respectively -X- _ I-Outcome
) -X- _ I-Outcome
. -X- _ O
Interestingly -X- _ O
, -X- _ O
the -X- _ O
expression -X- _ B-Outcome
density -X- _ I-Outcome
of -X- _ I-Outcome
E-CR1 -X- _ I-Outcome
was -X- _ I-Outcome
found -X- _ I-Outcome
to -X- _ I-Outcome
fall -X- _ I-Outcome
significantly -X- _ I-Outcome
during -X- _ I-Outcome
the -X- _ I-Outcome
initiation -X- _ I-Outcome
and -X- _ I-Outcome
progressive -X- _ I-Outcome
phases -X- _ I-Outcome
( -X- _ O
weeks -X- _ O
1 -X- _ O
and -X- _ O
2 -X- _ O
after -X- _ O
the -X- _ O
disease -X- _ O
onset -X- _ O
) -X- _ O
and -X- _ O
gradually -X- _ B-Outcome
returned -X- _ I-Outcome
close -X- _ I-Outcome
to -X- _ I-Outcome
normal -X- _ I-Outcome
through -X- _ I-Outcome
their -X- _ I-Outcome
whole -X- _ I-Outcome
convalescent -X- _ I-Outcome
phase -X- _ I-Outcome
( -X- _ I-Outcome
beginning -X- _ I-Outcome
from -X- _ I-Outcome
weeks -X- _ I-Outcome
2 -X- _ I-Outcome
or -X- _ I-Outcome
3 -X- _ I-Outcome
to -X- _ I-Outcome
weeks -X- _ I-Outcome
7 -X- _ I-Outcome
or -X- _ I-Outcome
8 -X- _ I-Outcome
) -X- _ I-Outcome
in -X- _ I-Outcome
SARS -X- _ I-Outcome
patients -X- _ I-Outcome
irrespective -X- _ I-Outcome
CR1 -X- _ I-Outcome
genotype. -X- _ I-Outcome
In -X- _ O
conclusion -X- _ O
, -X- _ O
our -X- _ O
findings -X- _ O
, -X- _ O
at -X- _ O
least -X- _ O
, -X- _ O
suggest -X- _ B-Outcome
that -X- _ I-Outcome
E-CR1 -X- _ I-Outcome
is -X- _ I-Outcome
likely -X- _ I-Outcome
involved -X- _ I-Outcome
in -X- _ I-Outcome
immune -X- _ I-Outcome
pathogenesis -X- _ I-Outcome
of -X- _ I-Outcome
SARS -X- _ I-Outcome
disease -X- _ I-Outcome
. -X- _ O

